CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China

Summary

The industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by team of industry experts.

The Chinese pharmaceutical industry - comprising the manufacturing of Western Medicines, Active Pharmaceutical Ingredients (API), Traditional Chinese Medicine (TCM), Biologics and Herbal Medicines - was valued at $168.6 billion in 2010 and grew to $424.6 billion in 2016. In 2010, the pharmaceutical market for western medicine was worth $53.8 billion, which increased to $106 billion in 2016 at a CAGR of 12%. It is forecast to be $132.9 billion in 2018 and reach $209 billion by 2022. The Chinese medical device market was valued at $36 billion in 2015, which increased to $40.1 billion in 2017. Since 2015, the China Food and Drug Administration (CFDA) has released several policies to reform the pharmaceutical market. Reforms to clinical trial processes have helped to reduce R&D costs and time, while initiatives for the market authorization process have helped to minimize regulatory delays.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the China, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market (Pfizer, Merck, Novartis, Jiangsu Hengrui Medicine, Sinopharm and Tong Ren Tang) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Boston Scientific and Shinva)
- Detailed analysis about recent completed deals in the pharmaceutical and medical device market of China
- Porters five forces analysis for pharmaceutical and medical devices market of China
- An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
- Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the Chinese healthcare market.

Reasons to buy

This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving the Chinese healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
- Identify, understand, and capitalize on the opportunities and challenges in the Chinese healthcare market.

Executive Summary
Overview of Pharmaceutical Market
Overview of Medical Device Market
Deals Analysis
Porters Five Forces Model
Market Access
Country Healthcare Landscape
Opportunities and Challenges
Appendix

List Of Tables

Table 1: Biosimilars in Development by Chinese Companies, China, 2016 27
Table 2: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016 29
Table 3: Ophthalmic Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2015 53
Table 4: Orthopedic Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2017 54
Table 5: Diagnostic Imaging Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2015 55
Table 6: Nephrology and Urology Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2016 56
Table 7: Cardiovascular Devices Market, China, Revenue ($m) and Market Share (%) of Major Companies, 2017 57
Table 8: Drug Classification System, China, 2017 100
Table 9: Medical Device Classification, China, 2016 103
Table 10: Trademark Process Timeline, China, 2017 108
Table 11: Documents for Advertising Application, China, 2017 110
Table 12: Label/Insert Sheet Information, China, 2017 111
Table 13: Key Improvement Indicators, Healthy China 2030 115
Table 14: Trade Fairs, China, 2018-2019 125

List Of Figures

Figure 1: Pharmaceutical Market, China, Revenue ($bn), 2010-2017 8
Figure 2: Medical Device Market, China, Revenue ($bn), 2015-2020 8
Figure 3: Country Profile, China, 2017 14
Figure 4: Pharmaceutical Market, China, Revenue ($bn), 2010-2017 16
Figure 5: Pharmaceutical Market, China, Revenue Forecast ($bn), 2018-2022 16
Figure 6: Pharmaceutical Exports ($bn), China, 2010-2017 18
Figure 7: Top Export Partners, China, 2017 18
Figure 8: Pharmaceutical Imports ($bn), China, 2010-2017 19
Figure 9: Top Import Partners, China, 2017 19
Figure 10: USTR Findings, 2018 20
Figure 11: US-China Trade War Timeline, 2018 23
Figure 12: Pharmaceutical Drug Sales Channel, China, 2016 23
Figure 13: Supply Chain Prior to 2017 24
Figure 14: Two Invoice System 24
Figure 15: Policies for Biosimilar Promotion, China, 2018 27
Figure 16: Major Biosimilar Sales ($m), China, 2016 27
Figure 17: Traditional Chinese Medicine Production (10,000 tons), China, 2010-2016 28
Figure 18: Top 5 Therapeutic Areas by Incidence Rate (per 100,000 person), China, 2016 29
Figure 19: Pharmaceutical Market, Major Players, 2017 31
Figure 20: Medical Device Market, China, Revenue ($bn), 2015-2020 51
Figure 21: Medical Device Market, China, Revenue Forecast ($bn), 2021-2025 51
Figure 22: Medical Device Market, China, Revenue by Segment ($bn), 2017 52
Figure 23: Ophthalmic Devices Market, China, Revenue ($m), 2015-2022 53
Figure 24: Ophthalmic Devices Market, China, Market Share of Major Players (%), 2015 53
Figure 25: Orthopedic Devices Market, China, Revenue ($m), 2015-2020 54
Figure 26: Orthopedic Devices Market, China, Market Share of Major Companies (%), 2017 54
Figure 27: Diagnostic Imaging Devices Market, China, Revenue ($bn), 2015-2020 55
Figure 28: Diagnostic Imaging Devices Market, China, Market Share of Major Players (%), 2015 55
Figure 29: Nephrology and Urology Devices Market, China, Revenue ($m), 2015-2022 56
Figure 30: Nephrology and Urology Devices Market, China, Market Share of Major Players (%), 2016 56
Figure 31: Cardiovascular Devices Market, China, Revenue ($bn), 2015-2022 57
Figure 32: Cardiovascular Devices Market, China, Market Share of Major Players (%), 2017 57
Figure 33: Diagnostic Market, China, Revenue ($bn), 2015-2020 58
Figure 34: Diagnostic Market, China, Revenue ($bn), 2021-2025 58
Figure 35: Medical Device Market, China, Revenue ($bn) of Major Companies, 2017 60
Figure 36: Deal Value and Deal Count, Pharmaceutical Market, China, 2017-2018 80
Figure 37: Deal Value and Deal Count Quarterly, Pharmaceutical Market, China, 2017-2018 80
Figure 38: Deal Value and Deal Count Sub-types, Pharmaceutical Market, China, 2017-2018 80
Figure 39: Top Five Therapy Areas by Deal Value, Pharmaceutical Market, China, 2017-2018 81
Figure 40: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, China, 2017-2018 81
Figure 41: M&A Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count) 81
Figure 42: Venture Financing Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count) 81
Figure 43: Private Equity Deals by Therapy Area, Pharmaceutical Market, China, 2017-2018 (by value and count) 81
Figure 44: Medical Device Market Deals (by deal value, $bn), China, 2017-2018 82
Figure 45: Medical Device Market Deals (by deal count), China, 2017-2018 82
Figure 46: Medical Device Market Deals Share (by deal count), China, 2017-2018 82
Figure 47:Medical Device Market Deals Share (by deal value), China, 2017-2018 82
Figure 48: Medical Device, China, Top Therapy Area by Deal Value, 2017-2018 83
Figure 49: Medical Devices, China, M&A Deals by Therapy Area, 2017-2018 83
Figure 50: Medical Devices, China, Venture Financing Deals by Therapy Area, 2017-2018 83
Figure 51: Medical Devices, China, Top Therapy Area by Deal Number, 2017-2018 83
Figure 52: Medical Devices, China, Private Equity Deals by Therapy Area, 2017-2018 83
Figure 53: Healthcare System, China, 2017 88
Figure 54: National Reimbursement Drug List Process, China, 2017 89
Figure 55: National Reimbursement Drug List Classification, China, 2017 90
Figure 56: Public Insurance Schemes, China, 2017 91
Figure 57: Out-of-Pocket Expenditure (% of total expenditure on health), China, 2010-2017 93
Figure 58: Annual Rate of Change (%), Health Care Price Index, China, 2010-2016 93
Figure 59: Pricing Policies, China, 2017 94
Figure 60: Drug Movement from Market Authorization to Patient Use, China, 2016 95
Figure 61: Ministry of Food and Drug Safety, Organization Chart, 2017 96
Figure 62: Timeline of CFDA Reforms, China, 2015-2018 97
Figure 63: Center for Drug Evaluation Organization Chart, China, 2017 99
Figure 64: Drug Approval Process, China, 2017 101
Figure 65: Generic Drug Approval Process, China, 2017 102
Figure 66: Medical Device Approval Process, China, 2017 104
Figure 67: Patent Approval Process, China, 2016 106
Figure 68: Proposed Patent Linkage System, China, 2017 107
Figure 69: Trademark Process, China, 2017 109
Figure 70: Advertising Application Approval Process, China, 2017 110
Figure 71: Key Announcements and Updates, Healthy China 2020, 2009-2016 113
Figure 72: Healthy China 2030, Strategic Goals 114
Figure 73: Hospitals (Number), China, 2010-2017 117
Figure 74: Hospitals by Type (Number), China, 2010-2017 117
Figure 75: Diagnostic Equipment (installed base), China, 2015-2012 117
Figure 76: Hospital Beds (per 1,000 population), China, 2010-2017 118
Figure 77: Medical Institution Beds (Urban)(per 1,000 population), China, 2010-2017 118
Figure 78: Medical Institution Beds (Rural)(per 1,000 population), China, 2010-2017 118
Figure 79: Life Expectancy (in years), China, 2010-2017 119
Figure 80: Immunization Rate (%), China, 2010-2017 119
Figure 81: PM2.5 (g per m3), China, 2010-2017 120
Figure 82: CO2 Emissions (metric tons per capita), China, 2010-2017 120
Figure 83: Physicians (per 1,000 population), China, 2010-2017 121
Figure 84: Nurses (per 1,000 population), China, 2010-2017 121
Figure 85: Dentists, (per 1,000 population), China, 2010-2017 121
Figure 86: Pharmacists, (per 1,000 population), China, 2010-2017 121
Figure 87: Major Causes of Mortality (Death rate (%)), China, 2016 122
Figure 88: Major Causes of Male Mortality (Death rate (%)), China, 2016 122
Figure 89: Major Causes of Female Mortality (Death rate (%)), China, 2016 122
Figure 90: Disability-Adjusted Life Years by Major Disease (000), China, 2015 122
Figure 91: Healthcare Expenditure as Percentage of GDP (%), China, 2010-2017 123
Figure 92: Public-Private Share (%), China, 2010-2017 123
Figure 93: Opportunities & Challenges, China 127

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available